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Abstract
Background: The clinical application of stem cell therapy for myocardial infarction will require the
development of methods to monitor treatment and pre-clinical assessment in a large animal model, to
determine its effectiveness and the optimum cell population, route of delivery, timing, and flow milieu.
Objectives: To establish a model for a) in vivo tracking to monitor cell engraftment after autologous
transplantation and b) concurrent measurement of infarct evolution and remodeling.
Methods: We evaluated 22 dogs (8 sham controls, 7 treated with autologous bone marrow monocytes,
and 7 with stromal cells) using both imaging of 111Indium-tropolone labeled cells and late gadolinium
enhancement CMR for up to12 weeks after a 3 hour coronary occlusion. Hearts were also examined using
immunohistochemistry for capillary density and presence of PKH26 labeled cells.
Results: In vivo Indium imaging demonstrated an effective biological clearance half-life from the injection
site of ~5 days. CMR demonstrated a pattern of progressive infarct shrinkage over 12 weeks, ranging from
67–88% of baseline values with monocytes producing a significant treatment effect. Relative infarct
shrinkage was similar through to 6 weeks in all groups, following which the treatment effect was manifest.
There was a trend towards an increase in capillary density with cell treatment.
Conclusion: This multi-modality approach will allow determination of the success and persistence of
engraftment, and a correlation of this with infarct size shrinkage, regional function, and left ventricular
remodeling. There were overall no major treatment effects with this particular model of transplantation
immediately post-infarct.
Published: 27 April 2009
Journal of Cardiovascular Magnetic Resonance 2009, 11:11 doi:10.1186/1532-429X-11-11
Received: 27 November 2008
Accepted: 27 April 2009
This article is available from: http://www.jcmr-online.com/content/11/1/11
© 2009 Wisenberg et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Cardiovascular Magnetic Resonance 2009, 11:11 http://www.jcmr-online.com/content/11/1/11
Page 2 of 16
(page number not for citation purposes)
Background
Beginning in 2001, tremendous excitement was stimu-
lated regarding the potential to "heal" or reduce the extent
of necrosis following myocardial infarction, using trans-
planted progenitor cells. These early small animal studies
demonstrated a remarkable degree of reduction of myo-
cardial injury and improvement in left ventricular func-
tion [1-8]. Such enthusiasm was generated that a number
of clinical trials were conducted [9-14]. However, the
inconsistent and limited treatment effects in these recent
trials have tempered this enthusiasm [15,16].
Therefore, the question persists as to whether the early
results can be translated into the clinical realm. More
recent animal studies have cast further doubt regarding
the degree of engraftment, whether bone-marrow-derived
cells differentiate into cardiomyoctes [17,18], and
whether any therapeutic effect occurs. Assuming benefit,
there are several unanswered questions re: specific cell
lines, optimum route of delivery, timing, and regional
flow environment.
Resolution of these will require pre-clinical evaluation in
a large animal model to monitor the degree of engraft-
ment, and correlation with measurable treatment effects
on infarct evolution, including left ventricular remode-
ling.
There are potentially a number of different approaches for
in vivo cell tracking: paramagnetic iron oxide particle
labeling imaged with cardiovascular magnetic resonance
(CMR) [19-25]; radiolabeling of reporter probes [26-29];
and incorporation of radioactively labeled compounds
into transplanted cells with in vivo PET or SPECT [30]. In
our own hands, the use of a reporter probe in a large ani-
mal model (dog), did not appear to be feasible because of
high non-specific background uptake [31].
Cell labeling techniques are commonly applied to hemat-
opoetic cells using technetium, indium-based com-
pounds or fluorinated-2-de-oxy-glucose [32-36]. Indium
labeling has become established for tracking marrow-
derived cells in vivo [36,37], and we have chosen this
method to establish the presence, and degree of retention
of cells. A recent in vitro and phantom study in our labo-
ratory indicated that as few as 3,600 cells may be detected
with 111In SPECT [38]. This sensitivity is dependent on a
maximum average concentration of radioactivity of 111In
of 0.14 Bq/cell which we have shown can be safely incor-
porated without affecting viability, function, or prolifera-
tive capacity [38]. However, another laboratory has
suggested that much higher radioactive loading is possible
[39].
This study was undertaken to establish a method to con-
currently use SPECT and CMR to 1) monitor cell engraft-
ment, and 2) the effects of transplantation on infarct size,
regional function, and remodeling indices, in a canine
model of reperfused anterior myocardial infarction using
bone marrow-derived monocytes (BMMC's) [40-43] or
stromal (mesenchymal) cells [44-47], which have been
reported to have favorable effects on myocardial regener-
ation. The goals of this study were primarily to demon-
strate the ability to perform these assessments in the same
animal, and to determine the evolution of infarct-related
changes. By restricting the development and application
of techniques and technologies in a large animal model to
those already approved for human use, translation to
human use is assured.
Methods
Animal Preparation
Adult female bred-for-research hounds were used. All pro-
cedures were approved by the Animal Care Committee of
the University of Western Ontario, and were performed
according to the Guide of the Care and Use of Experimen-
tal Animals of the Canadian Council on Animal Care and
Use of Laboratory Animals, National Research Council.
We used a 3 hour left anterior descending occlusion/
reperfusion model with cells injected 3 hours after reper-
fusion, i.e. 6 hours after the onset of coronary occlusion.
The animals subsequently underwent serial imaging for
12 weeks, and then were sacrificed.
Cell Harvesting and Labeling
Preparation of Bone Marrow Mononuclear Cells and Bone Marrow 
Stromal Cells
In anticipation of autologous transplantation, under gen-
eral anesthesia, bone marrow was aspirated from either
the sternum or humerus with a heparinized syringe. The
marrow aspirate was diluted 1:3 with PBS and 8 mls was
layered over a 4 ml Ficoll cushion and centrifuged for 20
minutes at 430 g to pellet RBCs and platelets. BMMCs
were collected from the Ficoll/serum interface, pelleted at
430 g for 8 minutes and the pellet (containing RBCs and
BMMCs) resuspended in 10 mls PBS. Three volumes of
lysis buffer (high osmolarity ammonium chloride) were
added to the mixture and incubated on ice for 7 minutes
to selectively lyse RBCs, then centrifuged at 430 g for 8
minutes and the white BMMC pellet resuspended in 2 mls
PBS containing 5% FBS. Cells were counted on a hemacy-
tometer, washed with PBS and either used directly for
radioactive labeling and injection on the day of isolation
(BMMC) or cultured on plastic tissue culture dishes after
further isolation (stromal) (Falcon, VWR, Mississauga,
ON) in growth medium consisting of DMEM, 10% FBS,
glutamate and penicillin/streptomycin.Journal of Cardiovascular Magnetic Resonance 2009, 11:11 http://www.jcmr-online.com/content/11/1/11
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To obtain sufficient stromal cells for transplantation,
these cells were culture expanded for approximately 14
days. Specifically, the growth medium originally contain-
ing the BMMC's was changed twice weekly and the non-
adherent cells discarded. With washing, the hematopoi-
etic cells were washed away, and only the remaining
adherent stromal cells were retained. No unique mem-
brane marker was used for identifying stromal cells, but
they are generally considered to lack the c-kit, CD34 and
CD45 markers characteristic of Hematopoietic Stem Cells
(HSC) [48,49]. The stromal cell population is highly het-
erogeneous with respect to biomarkers and may contain
anywhere from 0.01 to 0.001% mesenchymal stem cells
(MSCs) [48]. In future experiments, these cells may be
enriched by FACS using MSC-specific markers such as
CD13, CD29 and CD44 [49]
111In Tropolone Labeling of Bone Marrow Cells
We previously have described 111In tropolone labeling of
cells [38]. Briefly, cells were incubated with 111In-tro-
polone in phosphate buffered saline (PBS) for 30 minutes
at 37°C. Then, cells were centrifuged at 430 g for 10 min
at 20°C. The supernatant was discarded and the pellet was
washed three times with PBS as described above. Typical
labeling efficiencies were ~60%. The combination of labe-
ling efficiency, number of cells incubated and dose of
radioactivity ensured that cells were labeled with < 0.14
Bq/cell, the dose we have previously demonstrated to
cause no adverse effects on cell viability and proliferation
[38] Labeled cells were typically transplanted by direct
injection within 90 minutes of the start of labeling.
We have investigated the correspondence between the
111In signal detected at the transplantation site and the
contribution to that signal by a) 111In inside viable cells,
b)  111In released by dead cells which have not been
cleared, and c) 111In leaked from viable cells and not
cleared [50]. We have discovered that there is a consistent
initial clearance of 111In with a biological half life of ~2
hours attributable to viable cells rapidly leaving the injec-
tion site. This initial clearance is followed by a slower
clearance attributed to the biological half life provided the
true biological half life of the transplanted cells is >1 and
<20 days. The lower limit is set by the rate of clearance of
111In labeled cellular debris and the upper limit by the
rate at which 111In leaks from viable transplanted cells.
The experiments performed in our laboratory and
reported by Blackwood et al [50] indicate that Indium
released by either viable or non-viable cells is not taken up
to any degree either by these stem cells or a rat embryonic
cardiomyoblast H9c2 cell line [50], and is rapidly cleared
from the site of injection.
Labelling BMMC and Stromal Cells with PKH26
PKH26 is a lipophilic marker inserted into the mem-
branes of viable cells [51], which cannot be passed from
cell to cell, and effectively labels the cell membrane. This
marker provided a means of identifying the transplanted
cells histologically following sacrifice. BMMC's and stro-
mal cells were completely trypsinized with a 1:50 dilution
of 20 mg % trypsin (Gibco/BRL, Burlington, Ontario,
Canada) for 10 min. Cells were washed once by centrifu-
gation for 8 min at 800 g followed by resuspension in
complete media with serum. This wash was then repeated
using Dulbecco's MEM (Gibco/BRL, Burlington, Ontario,
Canada) without serum. After cells were centrifuged a
third time, they were resuspended in 1 ml of Diluent C
(Sigma Chemical Co, St Louis, Missouri, USA) according
to the manufacturer's instructions. The PKH26 membrane
label (Sigma Chemical Co, St. Louis, Missouri, USA) was
prepared to a concentration of 15 ul of PKH26 stock (in
ethanol) in 1 ml of diluent C, and then added to the cell
suspension. Cells were incubated at room temperature
(RT) for 4 min with the tube inverted every minute. Fol-
lowing incubation, an equal amount of horse serum
(HyClone Labs Inc, Logan, Utah, USA) was added and
cells incubated for one minute. An equal volume of com-
plete media was added and cells were centrifuged as usual.
Cells were then washed two times with complete media to
remove any unbound label.
Surgical Preparation
Dogs were anesthetized using intravenous Propofol (1
ml/kg), intubated and ventilated with oxygen enriched
room air, and maintained with Isofluorane (2%). Follow-
ing thoracotomy, the left anterior descending coronary
artery was identified and ligated for 3 hours using a snare,
and then released. Eight control animals received only
injections of normal saline into the central and peri-inf-
arct areas 3 hours after release of the snare (6 hours from
the onset of the occlusion). Seven animals received an
injection of 2–3 × 107 BMMC's, and 7 animals, 1.5–1.7 ×
107 stromal cells, also 3 hours after snare release. These
animals were then imaged on a regular basis (as described
below) for 12 weeks and then sacrificed with potassium
chloride.
An additional five animals were studied to establish the
retention of the PKH26 cell labeling (3 animals with
BMMC's) and parameters for SPECT (2 animals). The 3
PKH26 animals were sacrificed at three weeks. For SPECT,
the animals were injected with stromal cells and imaged
at day 0 (surgery), 4, 7, 10 and 14 days.
Cell Transplantation
BMMC experiments
On the day of surgery, marrow was harvested and the cells
were separated and co-labeled with PKH-26 andJournal of Cardiovascular Magnetic Resonance 2009, 11:11 http://www.jcmr-online.com/content/11/1/11
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111Indium-tropolone. Cells were also mixed in India ink
for both gross and microscopic determination of the sites
of injection. We did not demonstrate any harmful effects
related to India ink. A small aliquot of cells was not
injected but maintained in culture and monitored daily
for 2 weeks. Autologous cells were injected directly into
the infarct and peri-infarct region (by visual assessment of
both discoloration and regional wall motion at the epicar-
dial surface) at multiple sites (8–10) using a 25-gauge nee-
dle.
Stromal cell transplantation
After the cells had been culture expanded for two weeks,
they were injected directly into the infarct and peri-infarct
regions, and imaging began. As was the case for the
BMMC's, a small aliquot of cells was kept in culture and
monitored.
Imaging Protocols and Analysis
CMR
CMR was performed on the day of surgery, and then
weekly to 8 weeks, and then at 10 and 12 weeks. CMR was
performed on a Siemens Avanto 1.5 T clinical scanner
using a rigid radiofrequency transmit/receive coil (Sie-
mens, CP Head coil). A mid-ventricular, transaxial gradi-
ent-echo 'scout' image was used to locate the long-axis
and short-axis (SAX) image-planes. Cine CMR for the
assessment of wall motion was obtained using a seg-
mented cineFLASH sequence with 5 lines per segment, 8–
12 segments per beat, TR/TE 10/4.8 ms, α = 20°, slice
thickness 8 mm, and a rectangular field of view (FOV,
175–250 × 400 mm).
For the assessment of infarct size, each imaging session
used a 0.2 mmol/kg bolus of Gd-DTPA (Magnevist, Berlex
Canada, Lachine, Québec, Canada), followed by a con-
stant infusion of 0.004 mmol/min/kg for 45–60 min, to
ensure a steady state [52-54]. This method has been vali-
dated in our laboratory in both canine and clinical set-
tings to provide excellent delineation of the extent of scar
and correlation with histological measurement of infarct
size [53]. Using this method removes the dependence on
the timing of imaging as a variable affecting the increase
in signal within the infarct zone as equilibrium is estab-
lished between blood and tissue concentrations of Gd-
DTPA [53]. The imaging sequence used for infarct size
evaluation was a segmented inversion-recovery turbo-
FLASH (irTFL, TR/TE 8.0/4.0 ms, α = 25°, TI chosen itera-
tively to null the normal myocardium), acquired after at
least 30 min continuous infusion, synchronized to the
cardiac cycle (at end diastole) and with breath holding
(respirator turned off). A stack of 6–7 (8 mm thick) con-
tiguous short-axis irTFL and cine MR images was acquired,
in order to obtain full LV coverage.
Left-ventricular Wall Motion Analysis
Cine CMR images were used to qualitatively assess left-
ventricular wall motion for every slice position and time-
point in each animal using a validated method [55]. To
briefly review, each short-axis slice was divided into six
segments (septal, infer-septal, antero-septal, lateral,
antero-lateral, and infero-lateral). For each segment of
every slice, a subjective quantitative score assesing wall
motion was assigned. Hyperkinetic wall motion was
assigned a score of 7, normal, 6, mildly hypokinetic 5,
moderately hypokinetic 4, severely hypokinetic 3, akinetic
2, and dyskinetic 1. Each individual cine was interpreted
by one of three experienced cardiologists (GW, PZ, and
SD), blinded to treatment and time-point of each study.
Only those segments with a baseline (immediately post-
infarction) wall motion score of 4 (moderately hypoki-
netic) or less (more severe) were analyzed for subsequent
treatment effects. Also, as there was considerable variation
in the extent of wall motion abnormalities initially (the
number of segments affected), only the average score for
each individual animal at any given time point were used
for treatment comparisons.
Analysis of Infarct Size
We have previously reported in detail our method for the
determination of infarct size [53,56] which is modeled
after the initial work of Kim [57]. For each irTFL image,
the endo- and epi-cardial borders were traced manually
using Analyze AVW software [58] (Mayo Clinic, Roches-
ter, Maine, USA). In a remote region, the signal intensity
(SI) was sampled and used to apply a semi-automatic seg-
mentation of the LV: a region was deemed 'infarcted' if it
consisted of pixels with SI >2 SD above that of remote (i.e.
normal) myocardium [57]. The total number of infarcted
pixels for all slices was determined and expressed as a per-
centage of the total in the LV. The latter parameter, cor-
rected for absolute volumes, was used for total left
ventricular volume (mass) and the endocardial contour
allowed determination of the end-diastolic volume.
Nuclear Medicine Imaging and Analysis
In the two animals imaged five times in 14 days, the pur-
pose was to determine a) the period of time over which
111In could be detected, and b) the anatomic location of
the cells with respect to the infarct during that time inter-
val. In one animal, stromal cells were injected into the inf-
arct while in the second animal, cells were injected into
both the infarct as well as the normal tissue at a distance
of 3 cm from the first injection site. For the second animal,
the signals from the two injection sites were analyzed sep-
arately.
Imaging was performed on a dual-head MillenniumMG
gamma camera (General Electric Healthcare Technolo-
gies, Waukishaw, WI) using medium-energy general pur-Journal of Cardiovascular Magnetic Resonance 2009, 11:11 http://www.jcmr-online.com/content/11/1/11
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pose collimators. Images were acquired on surgery day
(day 0), and repeated on days 4, 7, 10 and 14. Initially, a
20-min whole-body scan was acquired to assess the extent
of radio-tracer distribution. An 111In SPECT image, cen-
tered on the heart, was then acquired with a scan time
starting at 40 minutes on day 0 and gradually increasing
to 4 hours on day 14. Immediately following the 111In
imaging, 783 ± 70 MBq of 99mTc-labeled sestamibi was
injected. A 30-min 99mTc SPECT image was acquired one
hour after injection to both assess myocardial perfusion
and provide an anatomical context for the 111In images.
After background correction, the 111In projection data
were reconstructed incorporating resolution compensa-
tion, and then filtered with a 5.4 mm FWHM Gaussian fil-
ter. The reconstructed image array was 128 × 128 × 128
(2.7 mm isotropic voxel size). The sestamibi images were
reconstructed in a similar fashion and co-registered using
the Analyze AVW software package [58](Mayo Clinic,
Rochester, MN). A volume of interest (VOI) was defined
on the weighted sum of the five 111In images by threshold-
ing the indium volume at 3% of the maximum value. The
number of counts in this volume at each of the five imag-
ing days was used to determine the in vivo time-activity
curve (TAC) of the 111In activity. Additionally the TAC of
the 111In signal from the single-site animal was calculated
directly from the projection data (total counts minus the
background) and used to confirm the value obtained
from the images reconstructed from the projection data,
supporting our image-based approach.
The results from these preliminary dog experiments gave
consistent results. For all three injection sites, the signal
decayed mono-exponentially with similar biological half-
lives of approximately 5 days: (5.8, 5.1, and 5.6 days
respectively). Thus, we were able to simplify subsequent
acquisition and analysis. To determine the biological half
life of the cells at the injection site, we performed whole
body 111In scanning at only 3 time points: within 30 min-
utes of cell injection, 7 days later and again 14 days after
the transplantation. 111In scanning was done in three of
the seven dogs given BMMC's and four of the seven dogs
given stromal cells. The logistics of doing both 111In-scan-
ning and CMR during the same anesthetic period limited
the number of animals imaged with 111In, although all
had CMR as previously described.
The following analysis was done on the whole body scans.
On surgery day, the counts for the whole body and region
over the heart were calculated and background corrected.
The ratio of the activity inside the heart over the total
activity measured in the body was taken as the percentage
of 111In (stem cells) that remained in the heart after injec-
tion. On day 7 and 14, the counts over the region of the
heart were calculated and background and decay cor-
rected. The ratio of the decay-corrected counts in the heart
over the total activity measured on surgery day was taken
as the percent of In-111 (stem cells) that remained within
the heart.
Histological Analysis
Detection of fluorescently labeled cells at injection sites
Immediately following sacrifice, hearts were removed and
cut transversely from apex to base into 4–5 rings. Injection
sites were identified by India Ink staining and 1 cm blocks
of tissue containing injection sites were dissected and
snap frozen in OCT by immersion in melting isopentane
at -80°C. Blocks were then cut at 10 μM using a Leitz cry-
ostat and representative sections (those adjacent to the
India ink marker) were stained with hematoxylin and
eosin. Serial sections were analysed for PKH26 fluores-
cence using a Zeisss Axiophot fluorescence microscope at
10×, 40×, and 630× magnification using the TRITC filter
series to detect red fluorescence.
In the 3 preliminary studies, not included in data analysis
of treatment effect, dogs were euthanized at 3 weeks post-
injection (rather than 12 weeks) and injection sites ana-
lyzed for PHK26 labeled cells using a Leitz Axioplan fluo-
rescence microscope with the TRITC filter series. Serial
sections were analysed for Myosin Heavy Chain (MyHC)
immunofluorescence using a cardiac MyHC specific mon-
oclonal antibody (Mab 4A9). Hoesch 33258 was used to
stain nuclei.
Blood vessel density in heart sections
In light of numerous reports that stem cell injections can
promote angiogenesis through a paracrine mechanism
[59-61], injection sites from 6 control, 5 BMMC and 7
stromal injected dogs were examined for capillary density
using alkaline phosphatase histochemistry to identify
endothelial cells. Capillaries were identified as dark pur-
ple structures in phase contrast microscopy, either as spots
(in cross section) or short tubes (in longitudinal section).
Capillary density was quantified, as previously described
by Oshima et al [62]. Two injection sites were analysed for
each animal and 5 fields were counted at 400× magnifica-
tion for each injection site. Fields were typically located in
the myocardium near the infarct border, and were ran-
domly chosen using a random number generator (ie a
phone book). Vessel density was calculated per mm2.
Statistical Analysis
For each time point, an analysis of variance corrected for
repeated measures was conducted to determine signifi-
cant group differences. When a significant result was
observed, Tukey tests determined which groups were sig-
nificantly different. Results were considered significant
when the probability of a type one error was less thanJournal of Cardiovascular Magnetic Resonance 2009, 11:11 http://www.jcmr-online.com/content/11/1/11
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0.05. All data are presented as means plus/minus standard
error of the means (SEM).
In order to determine if the evolving changes in the extent
of scar was dependent on the initial infarct size at surgery,
a Pearson Product Moment Correlation was conducted for
the initial extent of the infarct at surgery vs. the percent
change in infarct size from surgery at all time points. A sig-
nificant correlation would suggest that normalization
would not be appropriate.
Results
Cell Viability
We have previously shown that bone marrow cells incu-
bated with 0.9 MBq of 111In or less per 5 million cells had
100% viability over 14 days in culture (0.14 Bq/cell with
a labeling efficiency of 80%) [38]. We also demonstrated
an excellent correlation (r = 0.99, P < 0.01) between the
subsequent proliferation rate of cells labeled with 0.9
MBq 111In-tropolone and that of unlabelled control cells.
In the present study,the aliquots of BMMCs and stromal
cells kept in vitro showed normal proliferation and viabil-
ity 2 weeks after they were labeled with 111Indium-tro-
plone and PKH-26, and mixed with India ink (results not
shown).
In Vivo Indium Imaging Data
Fig. 1A–E shows the location of the 111In radioactivity at
the injection site co-registered with the perfusion deficit
on the 99mTc MIBI images in the dog imaged at several
time points through to day 14.
The biological clearance of cells from the injection site
was described by a mono-exponential function giving the
following results: for the BMMC injected dogs 5.7 days,
4.4 days and 4.4 days giving an average of 4.8 days; for the
four stromal cell injected dogs: 4.6 days, 6.1 days, 5.9 days
and 4.7 days giving an average of 5.3 days.
MR Assessment of Scar Shrinkage, Wall Motion, 
Ventricular Mass and End Diastolic Volume (Figs 2, 3, 4 and 
5)
Despite attempts at creating similar sized infarcts between
animals and treatment groups, the groups had signifi-
cantly different baseline infarct sizes, on the day of surgery
(see Fig. 2A). The control group had infarcts involving 23
± 4% of the LV, the bone marrow monocyte group, 14 ±
3%, and the stromal group, 34 ± 5%. In all cases, the liga-
ture was placed in a similar anatomic location, just distal
to the first diagonal branch.
Because of these variances, we normalized these differ-
ences by determining the relative degree of infarct size
reduction from baseline over the course of 12 weeks to
assist in the analysis of treatment effects. To determine the
validity of this approach and in order to determine
whether or not initial infarct size, measured immediately
following surgery, was related to changes in infarct over
time, we conducted Pearson product-moment correla-
tions between infarct size at surgery and relative change in
infarct size at all times by groups separately. There was
only one significant correlation for the Stromal group
between initial infarct and relative changes in infarct at
week 1. That correlation was likely due to random experi-
mental error. With 30 correlations performed, the proba-
bility of a significant correlation due to chance alone is
1.5, indicating that one and a half correlations would be
significant due to chance alone. Thus, our analysis shows
that there were no associations between initial infarct size
and relative changes in infarct size over time. In order to
increase the range of infarct size, a supplemental analysis
was conducted that included cases for all groups at once.
There were no significant associations observed. Thus, the
infarct size at surgery does not predict changes in relative
infarct reduction over time. Any statements made about
treatment are not confounded by the initial infarct size.
Therefore, using the relative change as the index parame-
ter, all groups had almost exactly the same degree of rela-
tive scar reduction up to the 6 week point, (control -62.4
± 4.3%, stromal -64 ± 8.3%, and BMMC's -61.5 ± 5.6%)
beyond which the curves began to diverge (Figure 2B). At
12 weeks, the control animals had a 75 ± 5% reduction in
scar, stromal cells 67 ± 3%, and bone marrow monocytes
88 ± 5%, Using the 6 week time point as the reference
point, there was a statistically significant difference
between the degree of further infarct shrinkage beyond 6
weeks in the BMMC group in comparison to both the con-
trols (p = 0.046) and stromal animals (p = 0.032) (Fig
2C). Figure 5 shows in a representative CMR of a dog
heart, the infarct size reduction from week 1 to week 12.
Although there was an improvement in regional motion
by approximately two wall motion scores in all groups (of
those segments with a baseline score of 4 or less), there
was no difference in the degree of improvement between
treatments at 12 weeks (Figure 3).
For left ventricular volume (mass), there were modest dif-
ferences between groups with small declines over time
with the stromal animals having the greatest decrease
between 8–12 weeks (presumably related primarily to inf-
arct shrinkage) (Figure 4A). However, there was no differ-
ence in the increase in enddiastolic volume between
groups at any time (Figure 4B).
As we did not quantify retained cell numbers using SPECT
in these experiments, it is difficult to make any statements
regarding correlation of cell numbers and treatmentJournal of Cardiovascular Magnetic Resonance 2009, 11:11 http://www.jcmr-online.com/content/11/1/11
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Serial Transaxial SPECT images following Indium labeling and intravenous Tc-99m MIBI Figure 1
Serial Transaxial SPECT images following Indium labeling and intravenous Tc-99m MIBI. Panels A-E respectively 
are fused images of Tc-MIBI and 111In-labeled stromal cells in a dog at day 0, 4, 7, 10 and 14.
A B 
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Absolute and relative changes in infarct size over time Figure 2
Absolute and relative changes in infarct size over time. There was a progressive decline in both absolute (A) and rela-
tive (B) CMR measured infarct size, in comparison to baseline, for controls, and both treatment groups. Values are means ± SE. 
One way analyses of variance showed that significant group differences were observed in relative infarct size changes. Posthoc 
Tukey Tests showed significant paired group differences at 12 weeks when the 6 week time point was used as the reference 
point for further change. a-Control vs. BMMC p = 0.046, b-Stromal vs. BMMC p = 0.032,
A 
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effects. This will be an important component of future
experiments.
Identification of PKH26 labeled cells at injection sites
In the three animals sacrificed at 3 weeks, most serial tis-
sue sections showed PKH26 labeled cells interspersed
with the India ink used to label injection sites. As shown
in Fig. 6, Hoesch 33258 labeled nuclei and BMMC cells
were observed within the scar tissue, as demonstrated by
blue and red fluorescence, respectively. In some cases, red
PKH26 labeled cells co-expressed with Mab4A9 labeled
cardiac myosin heavy chain (MyHC) as indicated by yel-
low fluorescence in the overlay. This may be the result of
BMMCs fusing with host cardiomyocytes and/or transdif-
ferentiating into cardiomyocytes. PHK26 positive cells co-
expressing MyHC were relatively rare, comprising approx-
imately 2–4 cells per field. The presence of PKH26 positve
cells would be in keeping with the Indium activity seen in
the animals imaged with SPECT at 14 days and the clear-
ance half-life of 5.3 days in the stromal experimental
group.
When injection sites were examined from dogs eutha-
nized 12 weeks post-injection, fluorescence microscopy
detected PKH26 label associated with the extracellular
matrix and individual cells. However, the relative number
of labeled cells was much reduced from week 3 animals.
Again, the small number of cells identified would be pre-
dicted based on the clearance kinetics observed with
SPECT. It is difficult to comment on the correlation
between cell numbers seen at 12 weeks and the treatment
effect observed on CMR. In all cases, PKH26 label was
observed near India Ink used to mark injection sites. In
contradistinction to 3 weeks, immunofluorescent co-
Changes in regional wall motion scores Figure 3
Changes in regional wall motion scores. Although there was a progressive improvement in regional function in the infarct 
and peri-infarct areas by almost 2 wall motion scores, there was no difference between treatments at 12 weeks. Separate one 
way analyses of variance showed that significant group differences were observed at week one only, F(2,16) = 8.08, p < .01. 
Posthoc Tukey Tests showed significant paired group differences between a = Controls and BMMC, and c = Stromal and 
BMMC.
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localization of MyHC failed to detect PKH26 positive cells
which co-expressed MyHC.
Effect of Cell Injection on Angiogenesis
Of the three groups, the mononuclear and stromal stem
cell treated animals showed approximately a 1/3 increase
in the density of blood vessels within the peri-infarct
region compared to control animals (Fig 7). This was not
statistically significant (F (2,15) = 1.30; p = .30) perhaps
due to the small sample size (15 animals per group would
have been required if the same trends were maintained
(Sample Power 2.0, SPSS inc. 2000)).
Discussion
This study establishes the methodology for monitoring
cell retention at the site of transplantation and determin-
ing the impact of these injections upon a) the natural
change in infarct size, wall motion, and remodeling indi-
ces serially for a 12 week period. We have tracked cell
retention using the radioactive tracer Indium111 and the
fluorescent lypophyllic marker, PKH26, to co-label our
cells in vitro. Previously, we have shown that our labeling
procedure, at the radioactive doses used, does not affect
the survival, proliferation or differentiation of stromal
cells [38]. There has been concern that Indium labeling
may lead to harmful effects on cell function, but the
administered dose per cell was not provided in that pub-
lication [35]. SPECT of In111 has allowed us to evalaute
cell clearance kinetics, up to 2 weeks, and to correlate
these with measures of treatment effect. We observed a
rapid loss of 111In signal over a two week period post-
injection, and this correlated with a small number of PKH
positive cells at 12 weeks. Since SPECT could not detect
111In signal at 12 weeks post-injection, a direct compari-
son between 111In signal and the number of PKH26
labelled cells was not possible. However, rapid cell loss
has previously been described for muscle satellite cells
injected into skeletal muscle [63] and for satellite cells
injected into myocardium [64]. We do not know if this
observed rapid clearance is the result of cell death caused
by the relatively hostile inflammatory environment
present in recently infarcted myocardium used in our
model, the migration of cells away from the injection site,
or if the kinetics described only apply to the cell lines
used. We did not, in these experiments, quantify retained
cell numbers and therefore, we are not able to correlate
these with treatment effect.
While there was some evidence that BMMCs can transdif-
ferentiate into cardiomyocytes at 3 weeks post-injection
(Figure 6), this was a relatively rare event. We did not
observe BMMC or stromal cell-derived cardiomyocytes in
any of our treated dogs at 12 weeks.
Changes in left ventricular volume and enddiastolic volumes Figure 4
Changes in left ventricular volume and enddiastolic 
volumes. A The stromal cell animals had a significant decline 
in left ventricular volume (total mass) in comparison to both 
controls, and BMMC from 8 weeks through 12 weeks: b- 
stromal different from controls c- stromal different from 
BMMC. There were small increases in endiastolic volume 
over time but there were no differences between treat-
ments. The first data point on the graph is at the first week 
following surgery relative to the volume on the day of sur-
gery.
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Late gadolinium enhanced end diastolic images from one of the stromal cell animals on the day of infarction, left, and at 12  weeks, right Figure 5
Late gadolinium enhanced end diastolic images from one of the stromal cell animals on the day of infarction, 
left, and at 12 weeks, right. The initial image demonstrates a large infarct with a central area of no enhancement. Such a 
pattern is often seen with extensive microvascular injury leading to "no reflow" and failure of delivery of tracer to the central 
zone of infarction. The 12 week image demonstrates a considerable reduction in the extent of infarction, and thinning of the 
infarct area, with loss of this no reflow effect, and cavitary dilatation.
 
Identification and characterization of PKH26+ (fluorescent) labeled donor cells in damaged myocardium 3 weeks following  direct injection of Bone Marrow Mononuclear cells (BMMCs) into myocardium Figure 6
Identification and characterization of PKH26+ (fluorescent) labeled donor cells in damaged myocardium 3 
weeks following direct injection of Bone Marrow Mononuclear cells (BMMCs) into myocardium. A) Overlay of 
PKH26 fluorescence (red) on 160× bright field image of unfixed cryostat section reveals bright red foci, which represent 
engrafted PKH26+ donor BMMCs. B) Overlay of beta cardiac myosin heavy chain immunofluoresence (IF = green) with PHK26 
fluoresence (red) and Hoesch 33258 fluoresence (blue) reveals red donor cells at the interface between scar (left) and myocar-
dium (right). Yellow MyHC+/PKH26 + BMMCs derived cardiomyocytes can also be observed. (Mag 160×).Journal of Cardiovascular Magnetic Resonance 2009, 11:11 http://www.jcmr-online.com/content/11/1/11
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Our study demonstrates a therapeutic effect from the
injection of autologous BMMC's into the peri-infarct
region after 3 hrs of ischemia and 3 hrs of reperfusion,
when compared to controls or stromal cell-treated ani-
mals. Previous studies have demonstrated improved neo-
vascularization following transplantation of monocytes
in a murine model [65], a reduction in infarct size with
increased angiogenesis but no change in regional function
in a porcine model [66], alteration of LV remodeling indi-
ces in a rat model [67], and even improved angiogenesis
and cardiac function when cells were retroperfused
through the cardiac veins of pigs subject to a left anterior
descending occlusion [68].
Stromal cells have been claimed to produce superior myo-
cardial regeneration in rats [69,70], and a porcine model
[71], but only increased angiogenesis with no improve-
ment in scar reduction in a rat model [70]. These incon-
sistent literature reports leave uncertainty as to whether
cell therapy does provide reproducible evidence of benefit
in large animal models. It is our hope that the concurrent
use of MR to monitor changes in scar shrinkage, and cor-
relation of this with both cell retention kinetics and quan-
titative measure of cell retention (in future experiments),
will help to provide more concrete evidence to support
claims of treatment efficacy. Infarct shrinkage was the
parameter, which, in our hands, was associated with the
most consistent pattern of evolution, and the least inter-
animal variation through to 6 weeks. Beyond that point,
the curves began to diverge with a treatment effect with
the BMMC's. We would suggest that future studies focus
on this index parameter as a gauge of treatment response.
Further, our study provides a framework for planning
imaging studies to monitor the effect of cell therapy. We
recommend early post-infarct imaging, a repeat at 6
weeks, and then at the end-point of treatment, which may
be 12 weeks or longer. The pattern and degree of initial
infarct shrinkage may also allow calculation of the neces-
sary sample size needed to establish treatment effect.
Bar graph illustrating the vessel density (vessels/mm2) in the peri-infarct region of each experimental group Figure 7
Bar graph illustrating the vessel density (vessels/mm2) in the peri-infarct region of each experimental group. A 
total of five random fields of view (400×) bordering the infarct scar had vessel structures counted for two injection sites for 
each animal in each group. The number of capillaries for each animal was averaged and calculated per square millimeters and 
used to calculate the vessel density for each group +/- SD (control n = 6, mononuclear n = 5, stromal n = 7). Of the three 
groups, the mononuclear and stromal stem cell treated animals showed approximately a 1/3 increase in the density of blood 
vessels within the peri-infarcted region compared to control animals that received an infarct but no cells, but was not signifi-
cant due to the small number of animals per group (F 2,15 = 1.30; p = 30).
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Although Orlic claimed a major reduction in the extent of
infarct size [6,8], others have not been able to reproduce
these results using similar experimental methods [17,18].
While the cellular basis for improved cardiac function is
still unknown, recent studies suggest that any therapeutic
value may involve mechanisms that prevent ventricular
dilation, increase myocardial wall thickness (resulting in
improved cardiac output) and promote neo-angiogenesis
at the site of injury.
We did not see any evidence in our study of cellular differ-
entiation nor of fusion with existing constituents at 12
weeks. Rather, we witnessed the relatively rapid clearance
of cells from the injection sites with a half-life of about 5
days, suggesting that these marrow-derived cells could
only produce benefit through a transient paracrine effect
that persisted beyond their clearance. The rapid loss of
cells from injection sites has previously been described for
other target tissues, such as skeletal muscle [70], and cell
types such as cardioblasts [71], and is unlikely to be a con-
sequence of radiation effects. However, Tran claimed no
loss of cells from either infarct or normal myocardium
from 2 hrs to 7 days after injection in a rat infarct model
[72].
Also, Tran et al recently assessed in a rat model the useful-
ness of dual-isotope Tc-MIBI perfusion and Indium-oxine
cell labeling imaging to gauge the pattern of infarct evolu-
tion [37]. They found no significant shrinkage in the size
of the perfusion defect between the day of infarction and
1 month, in marked contradistinction to our CMR find-
ings. We used CMR because of its superb spatial resolu-
tion [73-77] and it would appear to be a more reliable way
of assessing infarct evolution than nuclear medicine-
based measures of myocardial perfusion. These depend
on sequestration of the perfusion tracer by metabolically
intact cells. Our CMR findings in the control animals are
consistent with those of Fieno et al who found that
between 3 days to 4–8 weeks following infarction, there
was a reduction in the extent of CMR signal enhancement
to 24 +/- 3% of the original values [78], or in effect, a 76%
reduction in scar size. Our study demonstrated a progres-
sive reduction in infarct size of 75% in the control group
at 12 weeks. Studies that look at a single time point, at sac-
rifice for example, may not appreciate the evolutionary
changes that have occurred, and may potentially detect no
differences in infarct size reduction with treatment if they
have vastly different baseline.
Conclusion
The present study showed minimal effects of cell therapy
on left ventricular remodelling indices, with no substan-
tive changes in regional function (using a relatively crude
measure) with only a trend towards increased capillary
density. However, this study does indicate that the com-
bined use of non-invasive imaging modalities will allow
the accurate assessment of this treatment through correla-
tion of the evidence of engraftment, and retention, with
indices of infarct size reduction and remodelling. Future
studies, administering cells at different time points after
infarction, should also include a means of quantitatively
establishing the number of engrafted cells by calibrating
the Indium images, and the concurrent assessment of the
extent of perfusion abnormality and scar using CMR.
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